Cargando…
TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients
Premenopausal breast cancer (BC) is a core tumor of Li-Fraumeni (LFS) and Li-Fraumeni-like (LFL) Syndromes, predisposition disorders caused by germline mutations in TP53 gene. In the Southern and Southeastern regions of Brazil, a specific TP53 germline mutation, c.1010G>A (p.Arg337His), was ident...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312227/ https://www.ncbi.nlm.nih.gov/pubmed/30596752 http://dx.doi.org/10.1371/journal.pone.0209934 |
_version_ | 1783383738481115136 |
---|---|
author | Hahn, Eriza Cristina Bittar, Camila Matzenbacher Vianna, Fernanda Sales Luis Netto, Cristina Brinckmann Oliveira Biazús, Jorge Villanova Cericatto, Rodrigo Cavalheiro, José Antônio de Melo, Márcia Portela Menke, Carlos Henrique Rabin, Eliane Leistner-Segal, Sandra Ashton-Prolla, Patricia |
author_facet | Hahn, Eriza Cristina Bittar, Camila Matzenbacher Vianna, Fernanda Sales Luis Netto, Cristina Brinckmann Oliveira Biazús, Jorge Villanova Cericatto, Rodrigo Cavalheiro, José Antônio de Melo, Márcia Portela Menke, Carlos Henrique Rabin, Eliane Leistner-Segal, Sandra Ashton-Prolla, Patricia |
author_sort | Hahn, Eriza Cristina |
collection | PubMed |
description | Premenopausal breast cancer (BC) is a core tumor of Li-Fraumeni (LFS) and Li-Fraumeni-like (LFL) Syndromes, predisposition disorders caused by germline mutations in TP53 gene. In the Southern and Southeastern regions of Brazil, a specific TP53 germline mutation, c.1010G>A (p.Arg337His), was identified at a population frequency of 0.3%, the highest value ever described for a TP53 germline variation. In Brazilian BC patients, carrier frequency can vary from 0.5% to 8.7%. The current study assessed carrier frequency by genotyping TP53 c.1010G>A in 2 BC groups: 1) 315 patients unselected for age of diagnosis and family history (FH) and 2) 239 patients diagnosed before 46 years and without Chompret criteria for LFS or LFL. One carrier was identified in group 1 (0.3%; CI 95% 0.1–1.76%) and six carriers in group 2 (2.5%; CI 95% 0.93–5.39%). The frequencies differed significantly between groups (p = 0.04). The mutation carrier frequency observed in group 2 could justify mutation testing in BC patients diagnosed before 46 years and without Chompret criteria for LFS or LFL. Further studies in larger samples of BC patients of different ages and regions of the country are necessary to provide more definitive TP53 p.Arg337His carrier frequencies in different scenarios. |
format | Online Article Text |
id | pubmed-6312227 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-63122272019-01-08 TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients Hahn, Eriza Cristina Bittar, Camila Matzenbacher Vianna, Fernanda Sales Luis Netto, Cristina Brinckmann Oliveira Biazús, Jorge Villanova Cericatto, Rodrigo Cavalheiro, José Antônio de Melo, Márcia Portela Menke, Carlos Henrique Rabin, Eliane Leistner-Segal, Sandra Ashton-Prolla, Patricia PLoS One Research Article Premenopausal breast cancer (BC) is a core tumor of Li-Fraumeni (LFS) and Li-Fraumeni-like (LFL) Syndromes, predisposition disorders caused by germline mutations in TP53 gene. In the Southern and Southeastern regions of Brazil, a specific TP53 germline mutation, c.1010G>A (p.Arg337His), was identified at a population frequency of 0.3%, the highest value ever described for a TP53 germline variation. In Brazilian BC patients, carrier frequency can vary from 0.5% to 8.7%. The current study assessed carrier frequency by genotyping TP53 c.1010G>A in 2 BC groups: 1) 315 patients unselected for age of diagnosis and family history (FH) and 2) 239 patients diagnosed before 46 years and without Chompret criteria for LFS or LFL. One carrier was identified in group 1 (0.3%; CI 95% 0.1–1.76%) and six carriers in group 2 (2.5%; CI 95% 0.93–5.39%). The frequencies differed significantly between groups (p = 0.04). The mutation carrier frequency observed in group 2 could justify mutation testing in BC patients diagnosed before 46 years and without Chompret criteria for LFS or LFL. Further studies in larger samples of BC patients of different ages and regions of the country are necessary to provide more definitive TP53 p.Arg337His carrier frequencies in different scenarios. Public Library of Science 2018-12-31 /pmc/articles/PMC6312227/ /pubmed/30596752 http://dx.doi.org/10.1371/journal.pone.0209934 Text en © 2018 Hahn et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Hahn, Eriza Cristina Bittar, Camila Matzenbacher Vianna, Fernanda Sales Luis Netto, Cristina Brinckmann Oliveira Biazús, Jorge Villanova Cericatto, Rodrigo Cavalheiro, José Antônio de Melo, Márcia Portela Menke, Carlos Henrique Rabin, Eliane Leistner-Segal, Sandra Ashton-Prolla, Patricia TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients |
title | TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients |
title_full | TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients |
title_fullStr | TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients |
title_full_unstemmed | TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients |
title_short | TP53 p.Arg337His germline mutation prevalence in Southern Brazil: Further evidence for mutation testing in young breast cancer patients |
title_sort | tp53 p.arg337his germline mutation prevalence in southern brazil: further evidence for mutation testing in young breast cancer patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312227/ https://www.ncbi.nlm.nih.gov/pubmed/30596752 http://dx.doi.org/10.1371/journal.pone.0209934 |
work_keys_str_mv | AT hahnerizacristina tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients AT bittarcamilamatzenbacher tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients AT viannafernandasalesluis tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients AT nettocristinabrinckmannoliveira tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients AT biazusjorgevillanova tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients AT cericattorodrigo tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients AT cavalheirojoseantonio tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients AT demelomarciaportela tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients AT menkecarloshenrique tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients AT rabineliane tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients AT leistnersegalsandra tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients AT ashtonprollapatricia tp53parg337hisgermlinemutationprevalenceinsouthernbrazilfurtherevidenceformutationtestinginyoungbreastcancerpatients |